European Union - English - EMA (European Medicines Agency)

n.v. organon - ganirelix - reproductive techniques, assisted; ovulation induction; infertility, female - pituitary and hypothalamic hormones and analogues - the prevention of premature luteinising-hormone surges in women undergoing controlled ovarian hyperstimulation for assisted reproduction techniques.in clinical studies, orgalutran was used with recombinant human follicle-stimulating hormone or corifollitropin alfa, the sustained follicle stimulant.

Egypt - English - EDA (Egyptian Drug Authority)

organon-holland - syrup - 0.05 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

organon laboratories limited - tetracycline hydrochloride -

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - etoricoxib 120mg; etoricoxib 120mg - film coated tablet - 120 mg - active: etoricoxib 120mg excipient: calcium hydrogen phosphate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry green 39k11529 purified water active: etoricoxib 120mg excipient: calcium hydrogen phosphate dihydrate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry green 39k11529 purified water - arcoxia is indicated for: · acute and chronic treatment of the signs and symptoms of osteoarthritis (oa) and rheumatoid arthritis (ra) · the management of ankylosing spondylitis (as) · treatment of acute gouty arthritis · relief of acute pain, including pain related to minor dental procedures · relief of chronic musculoskeletal pain the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapy i.e.paracetamol have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient; and · after assessment of the individual patient's overall risk factors for developing severe adverse events e.g. history of cardiovascular, renal or gastrointestinal disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - etoricoxib 60mg; etoricoxib 60mg - film coated tablet - 60 mg - active: etoricoxib 60mg excipient: calcium hydrogen phosphate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry green 39k11520 purified water active: etoricoxib 60mg excipient: calcium hydrogen phosphate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry green 39k11520 purified water - arcoxia is indicated for: · acute and chronic treatment of the signs and symptoms of osteoarthritis (oa) and rheumatoid arthritis (ra) · the management of ankylosing spondylitis (as) · treatment of acute gouty arthritis · relief of acute pain, including pain related to minor dental procedures · relief of chronic musculoskeletal pain the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapy i.e.paracetamol have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient; and · after assessment of the individual patient's overall risk factors for developing severe adverse events e.g. history of cardiovascular, renal or gastrointestinal disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - etoricoxib 90mg; etoricoxib 90mg - film coated tablet - 90 mg - active: etoricoxib 90mg excipient: calcium hydrogen phosphate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry white 39k18305 purified water active: etoricoxib 90mg excipient: calcium hydrogen phosphate dihydrate carnauba wax croscarmellose sodium magnesium stearate microcrystalline cellulose opadry white 39k18305 purified water - arcoxia is indicated for: · acute and chronic treatment of the signs and symptoms of osteoarthritis (oa) and rheumatoid arthritis (ra) · the management of ankylosing spondylitis (as) · treatment of acute gouty arthritis · relief of acute pain, including pain related to minor dental procedures · relief of chronic musculoskeletal pain the decision to prescribe a selective cox-2 inhibitor should only be made: · if non-pharmacological interventions and simple analgesic therapy i.e.paracetamol have been tried and found to lack analgesic efficacy or to have unacceptable adverse effects in the individual patient; and · after assessment of the individual patient's overall risk factors for developing severe adverse events e.g. history of cardiovascular, renal or gastrointestinal disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - betamethasone acetate 3 mg/ml; betamethasone sodium phosphate 3.9 mg/ml;   - solution for injection - active: betamethasone acetate 3 mg/ml betamethasone sodium phosphate 3.9 mg/ml   excipient: benzalkonium chloride dibasic sodium phosphate disodium edetate dihydrate monobasic sodium phosphate monohydrate water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - mometasone furoate 0.1%{relative}; mometasone furoate 0.1%{relative} - lotion - 0.1% w/w - active: mometasone furoate 0.1%{relative} excipient: hyprolose isopropyl alcohol monobasic sodium phosphate monohydrate phosphoric acid propylene glycol water active: mometasone furoate 0.1%{relative} excipient: hyprolose isopropyl alcohol monobasic sodium phosphate dihydrate phosphoric acid propylene glycol water - elocon cream, ointment and lotion are indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as psoriasis and atopic dermatitis. elocon lotion is also suitable for scalp psoriasis and seborrhoeic dermatitis.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - mometasone furoate 0.1%{relative}; mometasone furoate 0.1%{relative} - topical cream - 0.1% w/w - active: mometasone furoate 0.1%{relative} excipient: aluminium starch octenylsuccinate ceteareth-20 hexylene glycol phosphoric acid propylene glycol monostearate purified water stearyl alcohol titanium dioxide white beeswax white soft paraffin active: mometasone furoate 0.1%{relative} excipient: aluminium starch octenylsuccinate hexylene glycol phosphatidylcholines, soya, hydrogenated phosphoric acid purified water titanium dioxide white beeswax white soft paraffin - elocon cream is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid- responsive dermatoses, such as psoriasis and atopic dermatitis.

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - mometasone furoate 0.1%{relative} - topical ointment - 0.1% w/w - active: mometasone furoate 0.1%{relative} excipient: hexylene glycol phosphoric acid propylene glycol monostearate purified water white beeswax white soft paraffin